Avidity Biosciences ABOUT | MANAGEMENT DELIVERING A WORLD-CLASS TEAM At Avidity Biosciences, our commitment to rigorous and innovative science is matched only by our passion to see people’s lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse. Sarah Boyce President & CEO Arthur A. Levin, PhD Chief Scientific Officer W. Michael Flanagan, PhD Chief Technical Officer Michael MacLean Chief Financial Officer Joseph Baroldi Chief Operating Officer Teresa McCarthy Chief Human Resources Officer John W. Wallen III, PhD, JD General Counsel Joe Johnston SVP, Regulatory Affairs Elizabeth “Lisa” Ackermann SVP, Clinical Development © 2021 Avidity Biosciences EXPLORE About Platform Pipeline Patients Investors Contact Careers CONTACT 10578 Science Center Dr. Suite 125 San Diego, CA 92121 info@aviditybio.com Tel: 858-401-7900 FOLLOW LEGAL Terms of Use Privacy Policy Patents

Avidity Biosciences INVESTORS | OVERVIEW ABOUT AVIDITY Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Learn More STOCK PERFORMANCE NASDAQ: RNA $24.05 LAST PRICE -$0.11 (-0.43%) CHANGE 23.1K VOLUME $1.1B MARKET CAP VIEW MORE INVESTOR CONTACT Kath Gallagher SVP, Corporate Communications & Investor Relations kath.gallagher@aviditybio.com 858-401-7900 x550 EVENTS Avidity Biosciences Virtual Investor & Analyst Event Series – Vol 3. : Delivering on AOCs - FSHD THURSDAY, DECEMBER 9, 2021 11:00am - 12:30pm EST Add to Calendar Set Email Reminder VIEW ALL RECENT NEWS NOV 9, 2021 Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights NOV 4, 2021 Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™) NOV 2, 2021 Avidity Biosciences to Participate in Upcoming Investor Conferences OCT 18, 2021 FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 VIEW ALL © 2021 Avidity Biosciences EXPLORE About Platform Pipeline Patients Investors Contact Careers CONTACT 10578 Science Center Dr. Suite 125 San Diego, CA 92121 info@aviditybio.com Tel: 858-401-7900 FOLLOW LEGAL Patents